Apparently, late yesterday, Barvarian Nordic announced that Prostvac has failed to show efficacy in the Phase III PROSPECT trial of the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). Click here for Barvarian Nordic’s media release.
Filed under: Drugs in development, Management, Treatment | Tagged: Barvarian, mCRPC, Nordic, PROSPECT, Prostvac, trial | 4 Comments »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
